INTRODUCTION AND OBJECTIVES: Galectin-3, a multifunctional oncogenic protein, has been reported to play important roles of progression in a variety of cancer including prostate cancer through the regulation of cancer cell proliferation, apoptosis, invasion and metastasis. However, we also identified the frequent up-regulation of Galectin-3 in benign prostatic hyperplasia (BPH), yet its pathophysiological roles in BPH. Here, we report the involvement of Galectin-3 in the growth of BPH.
METHODS: To investigate the association of Galectin-3 expression and prostate volume, we examined serum Galectin-3 (pg/ ml) with ELISA method in non-cancer cohort and analyzed the correlation between Galectin-3 expression and prostate volume with Speaman's correlation coefficient. Next, to analyzed proliferation abilities and the effect of Galectin-3 on smooth muscle, we examined knockdown of Galectin-3 expression by siRNA in BPH1 cells (benign prostatic hyperplasia cell line) and a co-culture experiment of BPH1 and PrSMC (Normal Human Prostate Smooth Muscle. Cells). Moreover, to investigate biological function of Galectin-3, we examined the gene expression profiles in Galectin-3-depleted BPH1 cells with microarray and bioinformatics analyses.
RESULTS: Correlation analysis revealed that serum Galectin-3 (ng/ml) were correlated with prostate volume (R¼0.643 p¼0.023) ( Figure 1 ). Next, depletion of Galectin-3 suppressed cell proliferation in BPH1 cells. Moreover, depletion of Galectin-3 in BPH1 cells suppressed cell proliferation of PrSMC cells in a co-culture method, suggesting Galectin-3 enhanced proliferation of PrSMC cells. Bioinformatics analysis with GSEA revealed that depletion of Galectin-3 was involved in interferon a response and interferon a response and interferon ? response (FDR q value < 0.001) (Figure 2 ), suggesting Galectin-3 regulates the proliferation of PrSMC through interferon response.
CONCLUSIONS: Our findings suggest that Galectin-3 is significantly involved in the growth of BPH and a promising therapeutic target for patients with BPH. Alexander Tamalunas*, Anna Ciotkowska, Raphaela Waidelich, Christian G. Stief, Christian Gratzke, Martin Hennenberg, Munich, Germany INTRODUCTION AND OBJECTIVES: Medical treatment in benign prostatic hyperplasia (BPH) includes reduction of prostate size to prevent disease progression, complications, and surgery, and also reduction of prostate smooth muscle tone for rapid relieve of lower urinary tract symptoms (LUTS). Combination therapies are still required to target both at once. However, current medications are insufficient, causing high rates of patient non-compliance due to an unfavourable balance between side effects and efficacy, with discontinuation rates peaking up to 90% for combination therapies. Here, we investigated the effect of thalidomide on cellular functions including cytoskeletal organization and growth of prostate stromal cells.
METHODS: Experiments were carried out in an immortalized line of cultured human prostate stromal cells (WPMY-1). Cytoskeletal organization was visualized by phalloidin staining, while cell growth was assessed using an EdU assay. Cytotoxicity was addressed using CCK8.
RESULTS: Thalidomide significantly reduced the proliferation of WPMY-1 cells. This decline was progressive, with a significantly lower proliferation rate after 72 and 168 hours of incubation. In addition, this inhibition of proliferation was concentration-dependent. Thus, proliferation was reduced after 72 h from 58% for control to 32% and 27% for 200 mM and 300 mM, respectively (p<0.00001 for thalidomide vs. control), and after 168 h from 56% for control to 29% and 24% for 200 mM and 300 mM, respectively (p<0.01 and p<0.0003 for thalidomide vs. control). Using CCK8, no cytotoxic effects on WPMY-1 cells occurred after 72 and 168 h. In parallel, Thalidomide induced cytoskeletal disorganization: while the cellular shape of control cells was characterized by many long and thin protrusions containing bundles of actin filaments, this structure collapsed after treatment with thalidomide.
CONCLUSIONS: Thalidomide impairs human prostate smooth muscle growth of stromal cells, without showing cytotoxic effects. This is paralleled by a breakdown of the cytoskeleton, what may inhibit prostate smooth muscle contraction. Urodynamic effects in vivo and a possible application in BPH appear possible, as thalidomide is safe in male patients with prostate cancer. Functional studies merit further consideration.
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